STOCK TITAN

Medicus Pharma swaps $10.5M debt for preferred shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
424B3

Rhea-AI Filing Summary

Medicus Pharma Ltd.'s prospectus supplement covers 64,911 common shares issuable upon exercise of warrants and incorporates the company's November 13, 2026 current-report update.

Medicus exchanged $10.5 million of A-1 Note principal for 105,000 non-convertible, non-voting preferred shares at $100 each; the exchanged debt was extinguished, with no cash proceeds to the company. The preferred shares carry cumulative 8% annual dividends payable in kind. A separate registered direct offering closed with approximately $3.0 million in gross proceeds before expenses, excluding warrant-exercise proceeds; the company also completed private placements for approximately $1.25 million and ATM sales for approximately $0.35 million.

After these transactions, the company estimated unaudited pro forma shareholders' equity of approximately $3.0 million as of November 13, 2026, and believes it met Nasdaq's $2.5 million Equity Standard. Nasdaq had not confirmed compliance; the company may be subject to delisting if it does not evidence compliance at its next periodic report. Medicus also cited substantial doubt about its ability to continue as a going concern.

2 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major point$10.5 million of A-1 Note principal was extinguished in exchange for preferred shares. 2.8× market cap
  • Moderate pointThe company estimates approximately $3.0 million of pro forma equity and believes it met Nasdaq's $2.5 million Equity Standard.

Negative

  • Major pointThe company disclosed substantial doubt about its ability to continue as a going concern.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Nasdaq had not confirmed compliance; the company said it may be subject to delisting if it does not evidence compliance at its next periodic report.

Filing Explained

After the November 13 exchange, about 4.2 million dollars under the A Notes and 8.2 million dollars under the unchanged B Note remained outstanding.

The November 13 closing issued 97,973 common shares in the registered offering and 726,730 in private placements, and sold pre-funded warrants for up to 1,646,213 more shares; only exercise would issue the warrant shares, adding to the common-share count.

Each pre-funded warrant was sold for $1.7199 and is immediately exercisable for one share at $0.0001. Exercise is restricted if it would put a holder and related parties above 4.99% (or an elected 9.99%) beneficial ownership; exercise that would exceed 19.99% ownership or trigger a change of control is barred unless shareholders approve.

Common shares covered by prospectus supplement 64,911 shares Shares issuable upon exercise of warrants
A-1 Note principal exchanged $10.5 million Exchanged for 105,000 non-convertible, non-voting preferred shares
Preferred shares issued in exchange 105,000 shares Issued at $100 per share
Registered direct offering gross proceeds Approximately $3.0 million Before estimated offering expenses and excluding proceeds from Pre-Funded Warrant exercises
Common shares sold in registered direct offering 97,973 shares Priced at $1.72 per share
Pre-Funded Warrant Shares Up to 1,646,213 shares Each Pre-Funded Warrant is exercisable for one common share
Unaudited pro forma shareholders' equity Approximately $3.0 million Company estimate as of November 13, 2026, after the transactions
Nasdaq Equity Standard $2.5 million Company believes it regained compliance with this shareholders' equity standard
Pre-Funded Warrants financial
"Pre-Funded Warrants to purchase up to 1,646,213 Common Shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
cashless basis technical
"A holder may exercise a Pre-Funded Warrant for cash or on a “cashless” basis"
An agreement executed on a cashless basis lets a holder convert or exercise a security (like options, warrants, or conversion rights) without paying money upfront; instead the holder receives a smaller number of shares equal in value to what the cash would have purchased. Think of trading a coupon for fewer slices of a cake rather than handing over cash for the full slice. For investors, it affects how much ownership and dilution occur and avoids immediate cash outlays.
permanent shareholders' equity financial
"expects to classify the Preferred Shares as permanent shareholders' equity"
Market Value of Listed Securities regulatory
"its Market Value of Listed Securities (“MVLS”) had been below $35 million"
Market value of listed securities is the market value of the shares a company has listed on an exchange, calculated as the closing bid price multiplied by the number of listed shares. Exchanges use it as a continued-listing standard, so a company that stays under the required minimum receives a deficiency notice and is given a set period to recover before facing delisting.
Equity Standard regulatory
"maintain stockholders' equity of at least $2.5 million"
restricted securities regulatory
"are “restricted securities” within the meaning of Rule 144"
Restricted securities are shares or other investment instruments that come with legal or contractual limits on when and how they can be sold, like stock given to founders or bought in a private offering. Think of them as assets in a locked box that can’t be freely traded until certain conditions — such as a waiting period, company registration, or specific approvals — are met. For investors this matters because restricted securities are less liquid and can affect timing, price, and perceived value when they eventually enter the market.
Offering Type supplement
Securities Offered 64,911 Common Shares issuable upon exercise of warrants
Offering Amount 64,911 Common Shares

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares does the Medicus Pharma prospectus supplement cover?

The prospectus supplement covers 64,911 common shares issuable upon exercise of warrants. It incorporates the company's November 13, 2026 current-report update.

How much did MDCX's November 2026 registered direct offering raise?

The offering generated approximately $3.0 million in gross proceeds before estimated offering expenses, excluding proceeds from exercises of the Pre-Funded Warrants. It included 97,973 common shares at $1.72 per share and Pre-Funded Warrants to purchase up to 1,646,213 shares at $1.7199 per warrant.

What did Medicus Pharma exchange for preferred shares?

Medicus exchanged $10.5 million of A-1 Note principal for 105,000 non-convertible, non-voting preferred shares at $100 per share. The exchanged debt was extinguished, and the preferred shares carry cumulative dividends at 8% per annum, payable in additional preferred shares.

Has Nasdaq confirmed MDCX regained compliance?

No. Medicus said it believed it met the $2.5 million Equity Standard based on estimated unaudited pro forma shareholders' equity of approximately $3.0 million as of November 13, 2026, but Nasdaq had not confirmed compliance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-287599

PROSPECTUS SUPPLEMENT NO. 13

(to prospectus dated effective March 27, 2026)

Medicus Pharma Ltd.

64,911 Common Shares Issuable upon the Exercise of Warrants


This prospectus supplement amends and supplements the prospectus dated effective March 27, 2026, as supplemented or amended from time to time (the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333-287599). This prospectus supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 16, 2026 (the "Form 8-K"). Accordingly, we have attached the Form 8-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our common shares and warrants, with an exercise price of $4.64 and expiration date of November 15, 2029 (the "Public Warrants"), are listed on The Nasdaq Capital Market ("Nasdaq") under the symbols "MDCX" and "MDCXW," respectively. On November 13, 2026, the last reported sales prices of the common shares and Public Warrants were $1.95 and $0.20, respectively.

We are an "emerging growth company" under applicable Securities and Exchange Commission rules and are eligible for reduced public company disclosure requirements.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading "Risk Factors" beginning on page 7 of the Prospectus, and under similar headings in any amendment or supplements to the Prospectus.

None of the Securities and Exchange Commission, any state securities commission or the securities commission of any Canadian province or territory has approved or disapproved of the securities offered by this prospectus supplement or the Prospectus or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is November 16, 2026.


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2026

MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)

Ontario 001-42408 98-1778211
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

300 Conshohocken State Road, Suite 200
Conshohocken, Pennsylvania, United States 19428
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code: (610) 540-7515

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbols   Name of each exchange on which registered
Common shares, no par value   MDCX   NASDAQ Capital Market
Warrants, exercisable for common shares   MDCXW   NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 1.01. Entry into a Material Definitive Agreement.

Exchange Agreement

On November 13, 2026, Medicus Pharma Ltd. (the "Company") entered into and closed an exchange agreement (the "Exchange Agreement") with Streeterville Capital, LLC (the "Investor"). Pursuant to the Exchange Agreement, $10.5 million in principal amount of the Company's Secured Promissory Note A-1, issued on May 27, 2026 in the original principal amount of $12,864,225 (the "A-1 Note"), was partitioned from the A-1 Note into a new note (the "Partitioned Note"), and the Investor exchanged the Partitioned Note for 105,000 non-convertible, non-voting preferred shares of the Company (the "Preferred Shares"), in a form authorized under the Company's current Articles of Incorporation, as amended, at an issue price of $100 per Preferred Share (the "Exchange").

Upon the closing of the Exchange, the Partitioned Note was cancelled, the indebtedness exchanged under the A-1 Note was extinguished and the Company's obligations under the A-1 Note were reduced by the $10.5 million principal amount so exchanged. The unexchanged balance of the A-1 Note remains outstanding in accordance with its terms and continues to be secured by the security interests, guaranties and collateral agreements relating to the A-1 Note. The Company's Secured Promissory Note A-2, issued on September 1, 2026 (the "A-2 Note" and, together with the A-1 Note, the "A Notes"), was not affected by the Exchange. Following the Exchange, approximately $4.2 million of principal and accrued and unpaid interest remains outstanding under the A Notes, and the $8.2 million outstanding under the Company's Secured Promissory Note B, issued on May 27, 2026, was also not affected by the Exchange. The Company did not receive any cash proceeds from the Exchange.

The Preferred Shares are not convertible into the Company's common shares, no par value (the "Common Shares"), and do not carry voting rights, except as required by the Business Corporations Act (Ontario). The Preferred Shares carry cumulative dividends at a rate of 8% per annum, payable in kind in additional Preferred Shares. The Preferred Shares are redeemable at the option of the Company, upon prior written notice, at a redemption price of $100 per Preferred Share plus all declared and unpaid dividends thereon to, but excluding, the redemption date, without premium or penalty. Upon a liquidation, dissolution or winding up of the Company, the Preferred Shares entitle the holders thereof to $100 per Preferred Share plus all declared and unpaid dividends thereon, in priority to the holders of the Common Shares. The Company expects to classify the Preferred Shares as permanent shareholders' equity.

The foregoing description of the Exchange Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such document, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Registered Direct Offering

On November 13, 2026, the Company entered into a securities purchase agreement (the "Purchase Agreement") with certain investors (the "Purchasers"), pursuant to which the Company agreed to issue and sell to the Purchasers in a registered direct offering (the "Offering") (i) 97,973 Common Shares (the "Shares") at a price of $1.72 per Share and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,646,213 Common Shares (the "Pre-Funded Warrant Shares") at a price of $1.7199 per Pre-Funded Warrant, representing an aggregate of 1,744,186 Common Shares (including Pre-Funded Warrant Shares), for aggregate gross proceeds to the Company of approximately $3.0 million, before deducting estimated offering expenses payable by the Company and excluding any proceeds from the exercise of the Pre-Funded Warrants. The offering price per Share was the closing price of the Common Shares on The Nasdaq Capital Market ("Nasdaq") on November 12, 2026, and the offering price per Pre-Funded Warrant is equal to the offering price per Share less the $0.0001 exercise price of each Pre-Funded Warrant. The Offering closed on November 13, 2026.


The Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares were offered and sold pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-292475) (the "Registration Statement"), including the base prospectus dated December 29, 2025 included therein, and a prospectus supplement dated November 13, 2026, filed with the U.S. Securities and Exchange Commission (the "SEC") pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the "Securities Act"). The Company did not engage a placement agent or underwriter in connection with the Offering and did not pay any underwriting discounts, commissions or placement agent fees.

The Pre-Funded Warrants were offered in lieu of Shares to any Purchaser whose purchase of Shares in the Offering would otherwise result in such Purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the Purchaser, 9.99%) of the Common Shares outstanding immediately following the Offering. Each Pre-Funded Warrant is exercisable for one Common Share at an exercise price of $0.0001 per share, is exercisable immediately upon issuance and does not expire, and may be exercised until it is exercised in full. A holder may exercise a Pre-Funded Warrant for cash or on a "cashless" basis, and cashless exercise is mandatory for so long as there is no effective registration statement or current prospectus available for the issuance of the Pre-Funded Warrant Shares or the amount of securities registered and available for issuance is insufficient. A holder may not exercise any portion of a Pre-Funded Warrant to the extent that, after giving effect to the exercise, the holder (together with its affiliates and any persons acting as a group with it) would beneficially own more than 4.99% (or, at the holder's election prior to issuance, 9.99%) of the Common Shares outstanding immediately after giving effect to the exercise; a holder may increase or decrease this limitation upon notice to the Company, provided that it may not exceed 9.99% and any increase will not be effective until the 61st day after notice is delivered. In addition, in order to comply with Nasdaq's shareholder approval requirements, the Company may not effect the exercise of any Pre-Funded Warrant, and no Purchaser will be entitled to exercise any portion of any Pre-Funded Warrant, that would cause (i) such Purchaser (together with its affiliates and any other persons acting as a group together with the Purchaser or any of the Purchaser's affiliates) to beneficially own more than 19.99% of the number of Common Shares outstanding immediately after giving effect to the exercise or (ii) a "change of control" of the Company within the meaning of Nasdaq Listing Rule 5635(b), in each case unless and until the Company has obtained shareholder approval in accordance with Nasdaq rules. This limitation may not be waived, increased or otherwise modified by the Company or any Purchaser, other than upon, and to the extent of, such shareholder approval, and applies to any successor to any Purchaser or transferee of a Pre-Funded Warrant. The exercise price and the number of Pre-Funded Warrant Shares are subject to adjustment for share dividends, splits, combinations and similar events, and the Pre-Funded Warrants provide for participation in certain pro rata rights offerings and distributions and for alternate consideration upon a fundamental transaction (each as described in the Pre-Funded Warrants). The Pre-Funded Warrants will not be listed on any securities exchange.

The Purchase Agreement contains customary representations, warranties and covenants of the Company and the Purchasers. The obligation of the Purchasers to consummate the purchase of securities in the Offering was contingent on the consummation of the Private Placements described below.

The foregoing descriptions of the Purchase Agreement and the Pre-Funded Warrants do not purport to be complete and are qualified in their entirety by reference to the full text of the form of Purchase Agreement and the form of Pre-Funded Warrant, copies of which are filed as Exhibits 10.2 and 4.1, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

Private Placements

Concurrently with the Offering, on November 13, 2026, the Company completed private placements of an aggregate of  726,730 Common Shares for cash to a limited number of accredited investors consisting primarily of members of the Company's management and directors, with such purchases led by a $750,000 investment by Dr. Raza Bokhari, the Company's Executive Chairman and Chief Executive Officer (purchasing through a controlled entity), at a purchase price of $1.72 per Common Share, being the closing price of the Common Shares on The Nasdaq Capital Market on November 12, 2026, for aggregate gross proceeds of approximately $1.25 million (the "Private Placements"). The Common Shares issued in the Private Placements were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation S thereunder and are "restricted securities" within the meaning of Rule 144 under the Securities Act.


Item 3.02. Unregistered Sales of Equity Securities.

The information contained in Item 1.01 of this Current Report on Form 8-K with respect to the Exchange and the Private Placements is incorporated into this Item 3.02 by reference. The Preferred Shares were issued to the Investor in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act, or, alternatively, by Section 4(a)(2) of the Securities Act, and the Common Shares issued in the Private Placements were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation S thereunder.

This report shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Item 3.03. Material Modification to Rights of Security Holders.

The information contained in Item 1.01 of this Current Report on Form 8-K with respect to the Exchange and the Preferred Shares is incorporated into this Item 3.03 by reference.

Item 8.01. Other Events.

The information contained in Items 1.01, 3.02 and 3.03 of this Current Report on Form 8-K is incorporated into this Item 8.01 by reference.

In connection with the Offering, the Company is filing as Exhibit 5.1 the opinion of Bennett Jones LLP regarding the validity of the issuance of the Shares and the Pre-Funded Warrant Shares and as Exhibit 5.2 the opinion of Paul, Weiss, Rifkind, Wharton & Garrison LLP regarding the validity of the Pre-Funded Warrants, together with the related consents as Exhibits 23.1 and 23.2, each for incorporation by reference into the Registration Statement.

Additionally, since the quarter ended September 30, 2026 and as of November 12, 2026, the Company has completed sales of approximately 113,000 Common Shares under its at-the-market offering program for gross proceeds to the Company of approximately $0.35 million (the "ATM Sales" and, together with the Exchange, the Offering and the Private Placements, the "Transactions").

As previously disclosed in the Company's Current Report on Form 8-K filed with the SEC on May 27, 2026, on May 20, 2026, the Company received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that its Market Value of Listed Securities ("MVLS") had been below $35 million for the previous 30 consecutive business days and that it was therefore not in compliance with Nasdaq Listing Rule 5550(b)(2). The Notice also stated that the Company did not then satisfy either of the alternative continued listing standards under Nasdaq Listing Rule 5550(b)(1) or 5550(b)(3). The Company was provided a compliance period of 180 calendar days, or until November 16, 2026, to regain compliance with the MVLS requirement or satisfy an alternative listing standard, including the requirement to maintain stockholders' equity of at least $2.5 million under Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard").

As a result of the completion of the Transactions, including the extinguishment of the indebtedness exchanged for the Preferred Shares, which the Company expects to classify as permanent shareholders' equity, and the issuance of Common Shares and Pre-Funded Warrants in the Offering and of Common Shares in the Private Placements and the ATM Sales, the Company has increased its shareholders' equity and believes that, as of November 13, 2026, after giving effect to the Transactions, its unaudited pro forma shareholders' equity was approximately $3.0 million. Accordingly, the Company believes that it has regained compliance with Nasdaq Listing Rule 5550(b) by satisfying the Equity Standard.


The pro forma shareholders' equity amount reflects the Company's preliminary assessment of the accounting treatment of the Transactions, including classification of the Preferred Shares as permanent equity, the net proceeds of the Offering, the Private Placements and the ATM Sales and the Company's estimated results of operations from October 1, 2026 through November 13, 2026. Nasdaq has not yet confirmed that the Company has regained compliance with its financial continued listing requirements. The Company expects that Nasdaq will continue to monitor the Company's ongoing compliance with the Equity Standard and, if at the time of its next periodic report the Company does not evidence compliance, the Company may be subject to delisting. There can be no assurance that Nasdaq will determine that the Company has regained compliance as a result of the Transactions, or that the Company will be able to maintain compliance with the Equity Standard or Nasdaq's other continued listing requirements in the future.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description
4.1 Form of Pre-Funded Warrant.
5.1 Opinion of Bennett Jones LLP.
5.2 Opinion of Paul, Weiss, Rifkind, Wharton & Garrison LLP.
10.1 Exchange Agreement, dated November 13, 2026, by and between Medicus Pharma Ltd. and Streeterville Capital, LLC.
10.2 Form of Securities Purchase Agreement, dated November 13, 2026, by and among Medicus Pharma Ltd. and the purchasers signatory thereto.
23.1 Consent of Bennett Jones LLP (included in Exhibit 5.1).
23.2 Consent of Paul, Weiss, Rifkind, Wharton & Garrison LLP (included in Exhibit 5.2).
104 Cover Page Interactive Data File (embedded within the inline XBRL document).

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, as well as "forward-looking information" within the meaning of applicable Canadian securities laws (collectively, "forward-looking statements"). Such forward-looking statements include, but are not limited to, statements concerning the anticipated accounting treatment and expected effects of the Transactions, including the classification of the Preferred Shares as permanent shareholders' equity, the anticipated increase in the Company's shareholders' equity and the Company's unaudited pro forma shareholders' equity, the Company's belief that it has regained compliance with Nasdaq Listing Rule 5550(b) by satisfying the Equity Standard, any determination by Nasdaq regarding the Company's compliance, the continued listing of the Common Shares and the Company's warrants on Nasdaq, and the Company's ability to maintain compliance with the Equity Standard and Nasdaq's other continued listing requirements in the future. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. In addition, forward-looking statements are typically identified by words such as "plan," "believe," "goal," "target," "aim," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "continue," "could," "may," "might," "possible," "potential," "predict," "should," "would" and other similar words and expressions, although the absence of these words or expressions does not mean that a statement is not forward-looking. Forward-looking statements are based on the current expectations and beliefs of the Company's management and are inherently subject to a number of factors, risks, uncertainties and assumptions and their potential effects. There can be no assurance that future developments will be those that have been anticipated. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, risks, uncertainties and assumptions, including, among others: the risk that the Company's final accounting review results in adjustments to the anticipated equity treatment or pro forma equity amount; the risk that ongoing operating losses reduce the Company's shareholders' equity below $2.5 million; the risk that Nasdaq does not concur that the Company has regained compliance; the risk of dilution to existing shareholders as a result of the Offering, the Private Placements and any exercise of the Pre-Funded Warrants; the Company's need for substantial additional funding and the substantial doubt about its ability to continue as a going concern; the risk that the Company fails to maintain compliance as of its future periodic reports and is subject to delisting; and the other risks and uncertainties described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as amended, originally filed with the SEC on March 25, 2026, and in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 6, 2026, and in the Company's other filings with the SEC and on SEDAR+. Potential investors, shareholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company does not assume any obligation to publicly update any forward-looking statement after it was made, whether as a result of new information, future events or otherwise, except as required by law or regulation. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements and the discussion of risk factors contained in the Company's filings with the SEC and the Canadian securities regulatory authorities, which are available on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

  MEDICUS PHARMA LTD.
     
  By: /s/ Raza Bokhari
  Name: Dr. Raza Bokhari
  Title: Executive Chairman and Chief Executive Officer

 Dated: November 16, 2026


Keep reading